Physician profile
Abbey Bruno
NPI 1669994927
$8,305.93
in general payments reported to CMS, 2019-2025
66 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.70 · 2022: $525 · 2023: $2,793 · 2024: $2,590 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,519 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,518.53 |
| Education | $185.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $646.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $594.88 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $498.43 | 2023-2025 | Darzalex, Erleada, Talvey |
| Daiichi Sankyo INC. | $417.98 | 2022-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $380.89 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Regeneron Healthcare Solutions, INC. | $298.70 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $287.01 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Abbvie INC. | $283.49 | 2021-2025 | |
| Incyte Corporation | $264.60 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $259.38 | 2021-2025 | Ojjaara, Shingrix, Jemperli |
| Genentech USA, INC. | $242.76 | 2023-2025 | Venclexta, Phesgo, Tecentriq |
| Pfizer INC. | $229.48 | 2023-2025 | |
| Genzyme Corporation | $219.35 | 2022-2025 | |
| Stemline Therapeutics INC. | $209.14 | 2023-2025 | Orserdu, Elzonris |
| Amgen INC. | $183.90 | 2023-2024 | Lumakras, Kyprolis, Evenity |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $181.82 | 2022-2025 | Xpovio |
| Eisai INC. | $177.46 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $172.31 | 2022-2025 | Clonoseq |
| Sobi, INC | $169.84 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.23 | 2022-2025 | |
| Sirtex Medical INC | $138.36 | 2023 | Sir-Spheres Microspheres |
| Emd Serono, INC. | $129.94 | 2023-2025 | Bavencio |
| Celgene Corporation | $123.47 | 2022-2025 | Pomalyst, Reblozyl, Opdualag |
| Jazz Pharmaceuticals INC. | $118.05 | 2023-2025 | |
| Lilly USA, LLC | $116.31 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Beigene USA, INC. | $92.77 | 2024-2025 | Brukinsa, Tevimbra |
| Puma Biotechnology, INC. | $90.63 | 2023-2025 | Nerlynx |
| Astellas Pharma US INC | $84.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $83.06 | 2023 | Akeega, Balversa, Erleada |
| Dendreon Pharmaceuticals LLC | $82.25 | 2023-2024 | Provenge |
| Mirati Therapeutics, INC. | $77.04 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $75.39 | 2022-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.89 | 2021-2023 | Gilotrif |
| Beone Medicines USA, INC. | $68.79 | 2025 | Brukinsa, Tevimbra |
| Seagen INC. | $68.07 | 2022-2023 | Adcetris |
| Apellis Pharmaceuticals, INC. | $56.50 | 2023 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $56.11 | 2023 | |
| Geron Corporation | $54.69 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $52.03 | 2023 | Zoladex |
| Servier Pharmaceuticals LLC | $51.78 | 2023-2024 | |
| Exelixis INC. | $51.33 | 2024-2025 | Cabometyx |
| Taiho Oncology, INC. | $50.65 | 2022-2023 | |
| Genmab U.S., INC. | $50.36 | 2023-2025 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $47.36 | 2022 | |
| Rigel Pharmaceuticals, INC. | $45.15 | 2023-2024 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $44.98 | 2025 | Braftovi, Tukysa, Mektovi |
| Gilead Sciences, INC. | $43.15 | 2023-2024 | |
| Pharmaessentia USA Corporation | $39.06 | 2024 | Besremi |
| Adc Therapeutics America, INC. | $32.02 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $30.50 | 2025 | |
| Blueprint Medicines Corporation | $29.13 | 2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $24.96 | 2024 | Qinlock |
| Alnylam Pharmaceuticals INC. | $23.60 | 2025 | Givlaari |
| Legend Biotech USA INC. | $21.76 | 2025 | Carvykti |
| Kite Pharma, INC. | $21.33 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $21.27 | 2025 | Enjaymo |
| Cti Biopharma Corp. | $20.59 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $20.43 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $19.86 | 2024 | Cosela |
| Sumitomo Pharma America, INC. | $19.67 | 2023 | Orgovyx |
| Coherus Oncology, INC. | $18.98 | 2024 | |
| Myovant Sciences INC. | $17.50 | 2022 | |
| Immunocore Limited | $16.79 | 2024 | Kimmtrak |
| Spectrum Pharmaceuticals INC. | $15.71 | 2025 | Rolvedon |
| Kyowa Kirin, INC. | $15.46 | 2024 | Poteligeo |
| Iovance Biotherapeutics, INC. | $14.55 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbey Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.